Close Menu

Genome Diagnostics NGSgo-MX11-3 Multiplexing for HLA Typing

Oct 20, 2020

Genome Diagnostics has launched NGSgo-MX11-3, its latest addition to a series of singleplex and multiplex amplification strategies for HLA typing by NGS. NGSgo-MX11-3 consists of amplification primers for eleven HLA genes — HLA-A, -B, -C, -DRB1, -DQB1 and -DPB1, DRB3/4/5, DQA1, and DPA-1 — in three mixes per sample. The three-tube design results in low noise levels and well-balanced alleles, making the data quality of the 11-loci multiplex similar to a singleplex strategy, Genome Diagnostics said. NGSgo-MX11-3 is available on a research-use-only basis. The firm anticipates that it will become available as a CE-marked IVD.

More Like This

Apr 12, 2021

Circulomics, Oxford Nanopore Technologies: Nanobind UL Library Prep Kit, Ultra-Long DNA Sequencing Kit

Circulomics and Oxford Nanopore Technologies have jointly launched two kits and a workflow to prepare ultra-high molecular weight DNA for sequencing. The method first uses the Circulomics Nanobind Big DNA Kit for DNA extraction. The DNA is then prepared for sequencing using the new Oxford Nanopore Ultra-Long DNA Sequencing Kit and the new Circulomics Nanobind UL Library Prep Kit. The workflow can result in 25 Gb of data per MinIon flow cell and 130 Gb per PromethIon flow cell with N50 read lengths of 100 kb or more.

Apr 12, 2021

Interpace Pharma Solutions: RNAscope ISH

Interpace Pharma solutions, a subsidiary of Interpace Biosciences has launched its RNAscope in situ hybridization (ISH) assay. The firm said RNAscope ISH uses "double Z" probes that simultaneously offer signal amplification and background noise control. Single-molecule visualization of the assay produces quantitative RNA expression and cell-specific expression in intact tissue architecture. The firm said that RNAscope ISH can be used to streamline immune checkpoint target identification, visualize in vivo delivery of CAR-T therapeutic products, and distinguish therapeutic gene sequence from endogenous transcripts selection, even when there is no known or validated antibody. 

Apr 08, 2021

CareDx European HLA Typing Service

CareDx has launched a research-use-only HLA typing service for customers in Europe out of its next-generation sequencing lab in Stockholm. The CareDx HLA typing service is powered by AlloSeq Tx17 and uses high-resolution hybrid-capture technology to yield a fast turnaround time with no long-range PCR inefficiencies. CareDx said that AlloSeq Tx17 provides over 50 percent more gene content than other commercial NGS solutions, including 11 classical HLA loci as well as HLA-E, -F, -G, -H, MICA, and MICB. A company spokesperson said that the service will be available to customers in the US later this year.

Apr 07, 2021

Synthego Eclipse Platform

Synthego has launched Eclipse, a CRISPR-based high-throughput cell engineering platform. The automated platform is cell-type agnostic, optimizes transfection, and provides end-to-end data tracking software. Applications include disease modeling, drug target identification and validation, and cell therapy manufacturing.

Apr 07, 2021

Qiagen QiaSeq Direct SARS-CoV-2 Kit

Qiagen has launched the QiaSeq Direct SARS-CoV-2 Kit, a viral genome enrichment and library preparation product that the company said significantly reduces library turnaround times and plastics use compared with ARTIC project protocols (primer-based approaches for next-generation sequencing that are considered the gold standard for SARS-CoV-2 genome sequencing). QiaSeq Direct SARS-CoV-2 supports sample multiplexing with up to 768 Dual Molecular Indices, unique markets tagged to molecules in a sample to eliminate downstream analysis errors. Starting from extracted viral RNA, the library prep workflow can be as little as four hours, Qiagen said. In addition, plastics usage can be reduced by as much as 50 percent. Qiagen said the new kit is supported by Qiagen's Digital Insights CoV-2 Insights Service, a cloud-based solution tailored to viral genome analysis, characterization, and reporting.

Apr 02, 2021

Bio-Techne Cultrex UltiMatrix Reduced Growth Factor Basement Membrane Extract

Bio-Techne has launched the Cultrex UltiMatrix Reduced Growth Factor Basement Membrane Extract (UltiMatrix RGF BME), an extracellular matrix hydrogel for culturing organoids and pluripotent stem cells. UltiMatrix RGF BME is a dependable, high-concentration cell scaffolding matrix with compositional and physical properties specifically designed for generating advanced 2D and 3D cell culture models. It features increased total protein content, optimized extracellular matrix protein composition, high levels of entactin, and improved tensile strength while reducing the dependency on supplemental growth factors, Bio-Techne said.

Apr 02, 2021

Hardy Diagnostics Autof MS 1000 MALDI-TOF Instrument

Hardy Diagnostics, in collaboration with Autobio, has launched the Autof MS 1000 matrix-assisted laser desorption/ionized time of flight (MALDI-TOF) instrument. The Autof MS 1000 provides high-speed identification and taxonomical classification of bacteria, yeasts, and filamentous fungi based on proteomic fingerprinting, with a database of approximately 5,000 species of microorganisms. The instrument is currently for research use only and will be available in markets that do not require US Food and Drug Administration 510(k) clearance, Hardy said.

Apr 01, 2021

MatMaCorp MY Real-Time Analyzer

Lincoln, Nebraska-based Materials and Machines Corporation, also known as MatMaCorp, has launched a rapid handheld molecular testing instrument called MY Real-Time Analyzer, or MYRTA, that performs PCR amplification or isothermal amplification and simultaneous real-time fluorescence detection. The device weighs less than one pound, can be held in one hand during operation, and can detect DNA or RNA targets within one hour, according to MatMaCorp. MYRTA can also process one sample with up to three different tests, and provides near quantitative information, including a Ct value.

Apr 01, 2021

10x Genomics Chromium Single-Cell Gene Expression Low Throughput Kit

10x Genomics has launched a new kit for low-throughput single-cell gene expression analysis on its Chromium platform.

The kit profiles gene expression for 100 to 1,000 single cells, lowering startup costs for experiments and enabling optimization of experimental conditions and sample prep for single-cell experiments. It works with demonstrated protocols for diverse sample types, including cell lines, primary cells, and dissociated tissue.

Apr 01, 2021

Thermo Fisher Scientific KingFisher Apex Purification System

Thermo Fisher Scientific has launched the Thermo Scientific KingFisher Apex Purification System, a high-throughput sample purification instrument for automated extraction of DNA, RNA, proteins, and cells from various sample types. The instrument is easy to use, saves time, and returns consistent results, the company said.

The KingFisher Apex enables nucleic acid, protein, and cell isolation while allowing users to customize protocols directly from the instrument to provide flexible, reproducible, and fast sample preparation without additional expense or complexity. It automates much of the work associated with the preparation of high-quality nucleic acids and proteins, can process 24 to 96 samples in 25 to 65 minutes, and elutes in volumes as low as 10 µL. 

The system can be used in combination with any of the Applied Biosciences MagMAX Isolation kits, as well as with Invitrogen Dynabeads Magnetic Separation products, Thermo Fisher said. Additional features include heating and cooling controls to maintain sample integrity, dual UV lights to safeguard against contamination, cloud-enabled access to up-to-date validated protocols, dual magnets to support small and large volume ranges, and the ability to elute in storage tubes to revisit samples later. It also has a touchscreen to allow users to write, edit, and run protocols directly on the instrument.

Apr 01, 2021

MilliporeSigma CRISPRi Whole-Genome Libraries and Pools

MilliporeSigma has launched its CRISPR inhibition (CRISPRi) whole-genome libraries and pools. CRISPRi is a useful tool for screening an entire genome, smaller gene family or individual targets. It modulates gene expression, allowing for robust loss-of-function studies, even in essential genes, with fewer off-target effects. The CRISPRi libraries libraries and pools were created by researchers at the University of California, San Francisco, and were further optimized by MilliporeSigma, resulting in improved algorithm design and scaffolding that has been proven to increase gene knock down, even in difficult-to-repress targets, the company said.

The libraries are fully customizable, contain the top five guide RNAs (gRNAs) and a subpool of five additional gRNAs per gene for a total of 10 gRNAs targeting every gene. They have defined subpanels to target specific gene groups including the druggable genome, cancer and apoptosis, membrane proteins, stress and proteostasis genes, and others. And the system includes 10x Genomics-compatibility for downstream single cell analysis, the firm said.

MilliporeSigma's gene modulation offering also includes CRISPR activation (CRISPRa) whole-genome libraries and pools.

Mar 31, 2021

Tempus NGS SARS-CoV-2 Assay

Tempus has launched an amplicon-based, high-throughput next-generation sequencing assay for the detection of SARS-CoV-2 virus mutations. The research-use-only assay includes primers designed to detect mutations and to characterize SARS-CoV-2 RNA.

Mar 31, 2021

Menarini Silicon Biosystems: CellSearch Circulating Myeloma Cells Assay

Menarini Silicon Biosystems has launched its CellSearch Circulating Multiple Myeloma Cells (CMMS) assay. The firm said the assay captures and enumerates CMMCs from peripheral blood samples. Menarini believes the assay offers significant standardization and sensitivity to monitor and understand multiple myeloma. 

Mar 29, 2021

Horizon Discovery: CRISPR Modulation Reagents

Horizon Discovery, a PerkinElmer company, has launched a new family of CRISPR modulation reagents for CRISPR interference, enabling researchers a better understanding of the biological pathways, processes, and pathologies of disease by repressing genes at the transcription level, and leading to new therapies.

The new reagents include what Horizon Discovery said are the first commercially available synthetic single guide RNAs for CRISPRi. Also included is a dCas9-SALL1-SDS3 repressor available in mRNA and lentiviral formats. The new technologies gives researchers the ability to repress genes in almost all cell lines, across any length of time, and at any scale, Horizon Discovery said.

Mar 24, 2021

Caris Life Sciences Human Leukocyte Antigen Genotype Reporting

Caris Life Sciences has launched Human Leukocyte Antigen (HLA) Genotype reporting. The product strengthens physicians' ability to provide more individualized treatment decisions for their patients, and the results may also provide additional insight for patient enrollment into clinical trials and patients' response to immunotherapy, the company said. 

Effective immediately, HLA Genotype results will be reported as a genomic signature, along with tumor mutational burden, microsatellite instability, and loss of heterozygosity as standard reporting elements for patients profiled by Caris.

NPR reports that researchers have developed chimeric embryos as part of work toward growing human organs in animals for organ transplants.

According to the Washington Post, the Biden Administration is set to make changes to federal restrictions on fetal tissue research.

In Science this week: approach to isolated trace DNA from archaic humans from sediments, and more.

Texas Monthly looks into the DNA Zoo being collected by Baylor College of Medicine researchers.

Sponsored by

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

Sponsored by

This webinar will discuss a recent study that characterized the relationships between SARS-CoV-2 RNAemia and disease severity, clinical deterioration, and extrapulmonary complications (EPCs).

Sponsored by

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.  

Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019.